Company: BIAF
Filing Date: 2025-05-23
Form Type: PRER14A
Source: 0001641172-25-012315
Chunk: 0

Company: bioAffinity Technologies, Inc.
Filing Date: 2025-05-23
Form: PRER14A
Chunk 0
---
<div align='center'>UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

SCHEDULE 14A

(Rule 14a-101)

SCHEDULE 14A INFORMATION

Proxy Statement Pursuant to Section 14(a) of the Securities
Exchange Act of 1934

(Amendment No. 1)</div>

Filed by the Registrant☒

Filed by a Party other than the Registrant☐

Check the appropriate box:

| ☒ | Preliminary Proxy Statement                                                     |
| ☐ | Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) |
| ☐ | Definitive Proxy Statement                                                      |
| ☐ | Definitive Additional Materials                                                 |
| ☐ | Soliciting Material Pursuant to §240.14a-12                                     |

<div align='center'>bioAffinity Technologies, Inc.

(Exact Name of Registrant as Specified in its Charter)

(Name of Person(s) Filing Proxy Statement, if other
than the Registrant)</div>

Payment of Filing Fee (Check the appropriate box):

| ☒ | No fee required.                                                                                    |
| ☐ | Fee paid previously with preliminary materials.                                                     |
| ☐ | Fee computed on table in exhibit required by Item 25(b) per Exchange Act Rules 14a6(i)(1) and 0-11. |

<div align='center'>bioAffinity Technologies, Inc.

3300 Nacogdoches Road, Suite 216

San Antonio, Texas 78217</div>

May [●], 2025

Dear Stockholder:

I am pleased to invite you to attend
the Annual Meeting of Stockholders (the “Annual Meeting”) of bioAffinity Technologies, Inc. (the “Company” or
“bioAffinity Technologies”) on Friday, July 25, 2025, at 8:00 a.m. Central Time. The Annual Meeting will be held in
person at the Company’s principal office at 3300 Nacogdoches Road, Suite 216, San Antonio, Texas 78217.

bioAffinity Technologies is committed to developing
noninvasive diagnostics for lung cancer and other diseases of the lung. Our team of scientists and business professionals is driven by
its mission to increase detection of cancer at early stage when accurate diagnosis leads to longer lives, fewer unnecessary invasive procedures,
reduced patient anxiety, and lower medical costs